Blandin AF, Durand A, Litzler M, Tripp A, Guérin É, Ruhland E, Obrecht A, Keime C, Fuchs Q, Reita D, Lhermitte B, Coca A, Jones C, Rebel IL, Villa P, Namer IJ, Dontenwill M, Guenot D, Entz-Werle N

Cancers (Basel). 2019 Nov 26;11(12):

Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells.

Reita D, Bour C, Benbrika R, Groh A, Pencreach E, Guérin E, Guenot D

Cancers (Basel). 2019 Oct 17;11(10):

RNA Aptamers Targeting Integrin α5β1 as Probes for Cyto- and Histofluorescence in Glioblastoma.

Fechter P, Cruz Da Silva E, Mercier MC, Noulet F, Etienne-Seloum N, Guenot D, Lehmann M, Vauchelles R, Martin S, Lelong-Rebel I, Ray AM, Seguin C, Dontenwill M, Choulier L

Mol Ther Nucleic Acids. 2019 May 24;17:63-77

Fireproofing of domestic upholstered furniture: Migration of flame retardants and potential risks.

Lounis M, Leconte S, Rousselle C, Belzunces LP, Desauziers V, Lopez-Cuesta JM, Julien JM, Guenot D, Bourgeois D

J. Hazard. Mater.. 2018 Dec 4;366:556-562

A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53.

Vidimar V, Licona C, Camacho RC, Guerin E, Coliat P, Venkatasamy A, Ali M, Guenot D, Le Lagadec R, Jung AC, Freund JN, Pfeffer M, Mellitzer G, Sava G, Gaiddon C

Cancer Lett.. 2018 Oct 16;:

Colon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8.

Laurent-Puig P, Marisa L, Ayadi M, Blum Y, Balogoun R, Pilati C, Le Malicot K, Lepage C, Emile JF, Salazar R, Aust D, Duval A, Selves J, Guenot D, Milano G, Seitz JF, Taieb J, Boige V, de Reyniès A

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii18

Laminin α1 orchestrates VEGFA functions in the ecosystem of colorectal carcinoma.

Mammadova-Bach E, Rupp T, Spenlé C, Jivkov I, Shankaranarayanan P, Klein A, Pisarsky L, Méchine-Neuville A, Cremel G, Kedinger M, De Wever O, Ambartsumian N, Robine S, Pencreach E, Guenot D, Simon-Assmann P, Goetz JG, Orend G, Lefebvre O

Biol. Cell. 2018 Jun 15;:

SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patients.

Emprou C, Le Van Quyen P, Jégu J, Prim N, Weingertner N, Guérin E, Pencreach E, Legrain M, Voegeli AC, Leduc C, Mennecier B, Falcoz PE, Olland A, Santelmo N, Quoix E, Massard G, Guenot D, Chenard MP, Beau-Faller M

Cancer Med. 2018 May 29;:

Influence of preoperative life satisfaction on recovery and outcomes after colorectal cancer surgery - a prospective pilot study.

Romain B, Rohmer O, Schimchowitsch S, Hübner M, Delhorme JB, Brigand C, Rohr S, Guenot D

Health Qual Life Outcomes. 2018 Jan 17;16(1):16

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.

Marisa L, Svrcek M, Collura A, Becht E, Cervera P, Wanherdrick K, Buhard O, Goloudina A, Jonchère V, Selves J, Milano G, Guenot D, Cohen R, Colas C, Laurent-Puig P, Olschwang S, Lefèvre JH, Parc Y, Boige V, Lepage C, André T, Fléjou JF, Dérangère V, Ghiringhelli F, de Reynies A, Duval A

J. Natl. Cancer Inst.. 2018 Jan 1;110(1):

Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1α axis inhibition.

Nguyen A, Moussallieh FM, Mackay A, Cicek AE, Coca A, Chenard MP, Weingertner N, Lhermitte B, Letouzé E, Guérin E, Pencreach E, Jannier S, Guenot D, Namer IJ, Jones C, Entz-Werlé N

Oncotarget. 2017 Sep 22;8(42):71597-71617

Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1a axis inhibition.

Nguyen A, Moussallieh FM, Mackay A, Cicek AE, Coca A, Pierre Chenard M, Weingertner N, Lhermitte B, Letouzé E, Guérin E, Pencreach E, Jannier S, Guenot D, Jacques Namer I, Jones C, Entz-Werlé N

Oncotarget. 2017 Mar;:

Histone hypoacetylation contributes to CXCL12 downregulation in colon cancer : impact on tumor growth and cell migration.

Romain B, Benbrika-Nehmar R, Marisa L, Legrain M, Lobstein V, Oravecz A, Poidevin L, Bour C, Freund JN, Duluc I, Guenot D, Pencreach E

Oncotarget. 2017 Mar;:

Perioperative bevacizumab improves survival following lung metastasectomy for colorectal cancer in patients harbouring v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue exon 2 codon 12 mutations†.

Renaud S, Schaeffer M, Falcoz PE, Seitlinger J, Romain B, Voegeli AC, Legrain M, Reeb J, Santelmo N, Rohr S, Brigand C, Olland A, Guenot D, Massard G

Eur J Cardiothorac Surg. 2017 Feb;51(2):255-262

Development of a memetic clustering algorithm for optimal spectral histology: application to FTIR images of normal human colon.

Farah I, Nguyen TN, Groh A, Guenot D, Jeannesson P, Gobinet C

Analyst. 2016 May;141(11):3296-304

Fully unsupervised inter-individual IR spectral histology of paraffinized tissue sections of normal colon.

Nguyen TN, Jeannesson P, Groh A, Piot O, Guenot D, Gobinet C

J Biophotonics. 2016 May;9(5):521-32

Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer.

Renaud S, Schaeffer M, Voegeli AC, Legrain M, Guérin E, Meyer N, Mennecier B, Quoix E, Falcoz PE, Guénot D, Massard G, Noël G, Beau-Faller M

Future Oncol. 2016 Jan;12(1):59-70

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.

Renaud S, Falcoz PE, Schaeffer M, Guenot D, Romain B, Olland A, Reeb J, Santelmo N, Chenard MP, Legrain M, Voegeli AC, Beau-Faller M, Massard G

Br J Cancer. 2015 Sep 15

Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification.

Weingertner N, Meyer N, Voegeli AC, Guenot D, Renaud S, Massard G, Falcoz PE, Olland A, Mennecier B, Gaub MP, Lindner V, Ghnassia JP, Quoix E, Chenard MP, Beau-Faller M

Pathology. 2015 Jun;47(4):320-8

Development of a hierarchical double application of crisp cluster validity indices: a proof-of-concept study for automated FTIR spectral histology.

Nguyen TN, Jeannesson P, Groh A, Guenot D, Gobinet C

Analyst. 2015 Apr 7;140(7):2439-48

KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.

Renaud S, Romain B, Falcoz PE, Olland A, Santelmo N, Brigand C, Rohr S, Guenot D, Massard G

Br J Cancer. 2015 Feb 17;112(4):720-8

PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer.

Manceau G, Marisa L, Boige V, Duval A, Gaub MP, Milano G, Selves J, Olschwang S, Jooste V, le Legrain M, Lecorre D, Guenot D, Etienne-Grimaldi MC, Kirzin S, Martin L, Lepage C, Bouvier AM, Laurent-Puig P

Cancer Med. 2015 Feb 2

Spatial organization of the tenascin-C microenvironment in experimental and human cancer.

Spenle C, Gasser I, Saupe F, Janssen KP, Arnold C, Klein A, van der Heyden M, Mutterer J, Neuville-Mechine A, Chenard MP, Guenot D, Esposito I, Slotta-Huspenina J, Ambartsumian N, Simon-Assmann P, Orend G

Cell Adh Migr. 2015 Jan 22:0.

Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients.

Prim N, Legrain M, Guerin E, Mennecier B, Weingertner N, Voegeli AC, Guenot D, Maugard CM, Quoix AE, Beau-Faller M

Eur Respir Rev. 2014 Sep;23(133):390-2

Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer.

Romain B, Hachet-Haas M, Rohr S, Brigand C, Galzi JL, Gaub MP, Pencreach E, Guenot D

Mol Cancer. 2014 Mar 14;13:58

Molecular markers for recurrence and sensitivity to preoperative chemoradiotherapy in locally advanced rectal tumours.

Romain B, Meyer N, Brigand C, Chenard MP, Schneider A, Guenot D

Dig Surg. 2014;31(4-5):347-53

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.

Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Flejou JF, Benchimol D, Berger A, Lagarde A, Pencreach E, Piard F, Elias D, Parc Y, Olschwang S, Milano G, Laurent-Puig P, Boige V

PLoS Med. 2013;10(5):e1001453

Role of Topoisomerases in Pediatric High Grade Osteosarcomas: TOP2A Gene Is One of the Unique Molecular Biomarkers of Chemoresponse.

Nguyen A, Lasthaus C, Guerin E, Marcellin L, Pencreach E, Gaub MP, Guenot D, Entz-Werle N

Cancers (Basel). 2013 Jun 4;5(2):662-75

Involvement of the TGFbeta pathway in the regulation of alpha5 beta1 integrins by caveolin-1 in human glioblastoma.

Cosset EC, Godet J, Entz-Werle N, Guerin E, Guenot D, Froelich S, Bonnet D, Pinel S, Plenat F, Chastagner P, Dontenwill M, Martin S

Int J Cancer. 2012 Aug 1;131(3):601-11

Integrin alpha5beta1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.

Janouskova H, Maglott A, Leger DY, Bossert C, Noulet F, Guerin E, Guenot D, Pinel S, Chastagner P, Plenat F, Entz-Werle N, Lehmann-Che J, Godet J, Martin S, Teisinger J, Dontenwill M

Cancer Res. 2012 Jul 15;72(14):3463-70

Cdx2 controls expression of the protocadherin Mucdhl, an inhibitor of growth and beta-catenin activity in colon cancer cells.

Hinkel I, Duluc I, Martin E, Guenot D, Freund JN, Gross I

Gastroenterology. 2012 Apr;142(4):875-885.e3

In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1alpha target genes and decreases tumor angiogenesis.

Guerin E, Raffelsberger W, Pencreach E, Maier A, Neuville A, Schneider A, Bachellier P, Rohr S, Petitprez A, Poch O, Moras D, Oudet P, Larsen AK, Gaub MP, Guenot D

Mol Med. 2012 Feb 10;18(1):83-94

Histologic characteristics of non-microsatellite-instable colon adenomas correlate with distinct molecular patterns.

Neuville A, Nicolet C, Meyer N, Schneider A, Legrain M, Brigand C, Duclos B, Bachellier P, Oudet P, Bellocq JP, Kedinger M, Gaub MP, Guenot D

Hum Pathol. 2011 Feb;42(2):244-53.

Targeted apc;twist double-mutant mice: a new model of spontaneous osteosarcoma that mimics the human disease.

Entz-Werle N, Choquet P, Neuville A, Kuchler-Bopp S, Clauss F, Danse JM, Simo-Noumbissie P, Guerin E, Gaub MP, Freund JN, Boehm N, Constantinesco A, Lutz P, Guenot D, Perrin-Schmitt F

Transl Oncol. 2010 Dec 1;3(6):344-53.

Evidence for various 20q status using allelotyping, CGH arrays, and quantitative PCR in distal CIN colon cancers.

Nicolet C, Guerin E, Neuville A, Kerckaert JP, Wicker N, Bergmann E, Brigand C, Kedinger M, Gaub MP, Guenot D

Cancer Lett. 2009 Sep 18;282(2):195-204

Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.

Pencreach E, Guerin E, Nicolet C, Lelong-Rebel I, Voegeli AC, Oudet P, Larsen AK, Gaub MP, Guenot D

Clin Cancer Res. 2009 Feb 15;15(4):1297-307

IR spectral imaging for histopathological characterization of xenografted human colon carcinomas.

Wolthuis R, Travo A, Nicolet C, Neuville A, Gaub MP, Guenot D, Ly E, Manfait M, Jeannesson P, Piot O

Anal Chem. 2008 Nov 15;80(22):8461-9

Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes.

Weber JC, Meyer N, Pencreach E, Schneider A, Guerin E, Neuville A, Stemmer C, Brigand C, Bachellier P, Rohr S, Kedinger M, Meyer C, Guenot D, Oudet P, Jaeck D, Gaub MP

Int J Cancer. 2007 Feb 1;120(3):524-32.

The microenvironment controls CDX2 homeobox gene expression in colorectal cancer cells.

Benahmed F, Gross I, Guenot D, Jehan F, Martin E, Domon-Dell C, Brabletz T, Kedinger M, Freund JN, Duluc I

Am J Pathol. 2007 Feb;170(2):733-44.

Primary tumour genetic alterations and intra-tumoral heterogeneity are maintained in xenografts of human colon cancers showing chromosome instability.

Guenot D, Guerin E, Aguillon-Romain S, Pencreach E, Schneider A, Neuville A, Chenard MP, Duluc I, Du Manoir S, Brigand C, Oudet P, Kedinger M, Gaub MP

J Pathol. 2006 Apr;208(5):643-52.

Cdx1 homeobox gene during human colon cancer progression.

Domon-Dell C, Schneider A, Moucadel V, Guerin E, Guenot D, Aguillon S, Duluc I, Martin E, Iovanna J, Launay JF, Duclos B, Chenard MP, Meyer C, Oudet P, Kedinger M, Gaub MP, Freund JN

Oncogene. 2003 Sep 11;22(39):7913-21.